Skip to content

Yi Wen

Nursing College of Wenzhou Medical University, Wenzhou, Zhejiang, China.

2 papers in the library · 9 citations · publishing 2024-2026

Papers

The effects of mindfulness therapy on infertile female patients: A meta-analysis.

Technology and health care : official journal of the European Society for Engineering and Medicine January 1, 2024 Yi Wen, Xinyan Li, Wan Shu et al. 9 citations

A meta-analysis of 14 randomized controlled trials involving 1784 patients found that mindfulness-based interventions, compared with conventional care, effectively relieve anxiety, depression, and perceived stress in women with infertility, and improve quality of life, including physiological function, role limitations due to physical problems, vitality, and mental health. The evidence suggests mindfulness therapy can reduce stress and enhance well-being, but the authors note that the quantity and quality of the literature are limited, calling for more multi-center, large-sample, high-quality randomized controlled trials.

Next-Generation Pharmacotherapy for Depressive Disorders: From Novel Compounds to Optimized Use of Available Drugs.

Drug design, development and therapy January 1, 2026 Fan Bu, Lan Qin, Zhengchi Lou et al.

Depressive disorders remain a leading cause of disability, and many patients do not achieve lasting remission with current treatments, especially those with treatment-resistant depression (TRD) or bipolar depression. This narrative review examines next-generation pharmacotherapy from a drug-centered and mechanism-informed perspective. It covers NMDA receptor modulators, dextromethorphan-bupropion, multimodal antidepressants, neuroactive steroids like brexanolone and zuranolone, psychedelic-assisted therapy, kappa-opioid receptor antagonists, and bipolar-specific mood stabilizers. The review also discusses optimizing existing drugs through repurposing, augmentation, combination therapy, and precision approaches like pharmacogenomics. Progress depends on both developing new compounds and improving treatment selection, sequencing, and monitoring across unipolar depression, bipolar depression, and TRD.